Almeida Silvana, Hutz Mara H
Fundação Faculdade Federal de Ciências Médicas de Porto Alegre, Departamento de Ciências Fisiólogicas, Porto Alegre, RS, Brazil.
Curr Opin Investig Drugs. 2007 Oct;8(10):814-20.
Genetic variation in estrogen-metabolizing genes and estrogen receptors influences estrogen metabolism and can potentially modify, at least in part, individual responses to hormone replacement therapy (HRT) or cardiovascular disease (CVD) susceptibility. Pharmacogenetics and association studies of estrogen metabolism genes and lipid levels, inflammatory markers, atherosclerosis and myocardial infarction are reviewed. The human estrogen receptor 1 gene is associated with estrogen metabolism and is the most frequently investigated gene. Few association studies between estrogen receptor 2 variants and CVD risk have been conducted. Although several phase I and II catabolism enzymes are responsible for critical steps in estrogen metabolism, genetic studies with these genes are scarce. Data presented here suggest that genetic variants might influence CVD risk and HRT response. However, no firm conclusions about the clinical implications of these markers can be made based on these studies.
雌激素代谢基因和雌激素受体的基因变异会影响雌激素代谢,并且至少在一定程度上可能会改变个体对激素替代疗法(HRT)的反应或心血管疾病(CVD)易感性。本文综述了雌激素代谢基因与血脂水平、炎症标志物、动脉粥样硬化和心肌梗死的药物遗传学及关联研究。人类雌激素受体1基因与雌激素代谢相关,是研究最频繁的基因。关于雌激素受体2变异与CVD风险之间的关联研究较少。尽管几种I相和II相分解代谢酶负责雌激素代谢的关键步骤,但针对这些基因的遗传学研究却很少。此处呈现的数据表明,基因变异可能会影响CVD风险和HRT反应。然而,基于这些研究尚无法就这些标志物的临床意义得出确凿结论。